Patents Examined by Marcia S. Noble
  • Patent number: 10441609
    Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 15, 2019
    Assignee: Miromatrix Medical Inc.
    Inventors: Harald Ott, Doris Taylor
  • Patent number: 10443045
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: October 15, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10426847
    Abstract: The present invention provides for the intratumoral delivery of at least one immunostimulatory cytokine in combination with at least one checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine using intratumoral electroporation. The checkpoint inhibitor may be administered systemically or encoded on a plasmid and delivered using intratumoral electroporation. The checkpoint inhibitor may be delivered contemporaneously with or after treatment with the immunomodulatory cytokine.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 1, 2019
    Assignee: OncoSec Medical Incorporated
    Inventors: Robert H. Pierce, Adil Daud
  • Patent number: 10428308
    Abstract: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 1, 2019
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Gordon M. Keller, Paul Gadue
  • Patent number: 10415044
    Abstract: Modified G6PC (glucose-6-phosphatase, catalytic subunit) nucleic acids and glucose-6-phosphatase-? (G6Pase-?) enzymes with increased phosphohydrolase activity are described. Also described are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing modified G6Pase-?. The disclosed AAV vectors and rAAV can be used for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia), and complications thereof.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 17, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Janice J. Chou
  • Patent number: 10414803
    Abstract: There is described an AAV capsid protein having an amino acid sequence which has at least 98% identity to the sequence of SEQ ID NO: 3 or at least 94% identity to the sequence of SEQ ID NO: 4. Also described is a pharmaceutical composition, an AAV capsid and a viral particle comprising the capsid protein, a recombinant AAV vector comprising a nucleotide sequence which encodes for the capsid protein, and a host cell and a transgenic animal comprising the capsid protein or the vector. In addition, there is described a method of transferring a nucleic acid of interest into a mammal comprising introducing a recombinant AAV vector into the mammal, wherein the recombinant AAV vector comprises a gene of interest which is encapsidated into a capsid comprising the capsid protein.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 17, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Amit Nathwani, Allison Dane
  • Patent number: 10413617
    Abstract: Methods and products for altering or promoting the development of heart tissue are disclosed. The methods include the use of nucleic acids of cardiogenic inducing factor for treating a subject having heart disease.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: September 17, 2019
    Assignee: The Texas A&M University System
    Inventors: Larry F. Lemanski, Ashley Arms, Andrei Kochegarov
  • Patent number: 10406242
    Abstract: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and/or injury.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: September 10, 2019
    Assignee: Emmetrope, Inc.
    Inventors: Jeffrey L. Goldberg, Alan Halpern
  • Patent number: 10391184
    Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.
    Type: Grant
    Filed: July 20, 2014
    Date of Patent: August 27, 2019
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Luis Tecedor, Yong Hong Chen
  • Patent number: 10385312
    Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: August 20, 2019
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 10376544
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 13, 2019
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 10376549
    Abstract: The present disclosure describes the generation and the use of Ad variants (Ad) possessing any combination of mutations in genes that code for the hexon, penton, fiber, and non-structural proteins, where simultaneous modification of hexon and penton are made to avoid the trapping of Ad in the liver and to reduce toxicity after intravascular virus administration. Such liver de-targeted Ad can be useful tool for selective and specific gene delivery to extra-hepatic tissues and cells, including disseminated metastatic cancer cells.
    Type: Grant
    Filed: January 17, 2016
    Date of Patent: August 13, 2019
    Assignee: ADCURE BIOTECHNOLOGIES, LLC.
    Inventors: Dmitry M. Shayakhmetov, Nelson C. Di Paolo
  • Patent number: 10370637
    Abstract: A method of culturing pluripotent stem cells is provided. The method includes culturing pluripotent stem cells in a pluripotent stem cell culture medium supplemented with an additive, where the additive includes a source of acetate ions, a carboxylic acid, or a physiologically acceptable salt of the carboxylic acid, or a combination of these substances, in an amount effective to maintain the pluripotent stem cells in culture in an undifferentiated pluripotent state. Also included are pluripotent stem cell culture media and methods of making such media.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 6, 2019
    Assignee: The Regents of the University of California
    Inventors: Prudence Talbot, Sabrina Lin, Antonio Loza
  • Patent number: 10369201
    Abstract: Disclosed herein are methods and compositions for diagnosing, treating or preventing Huntington's Disease.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: August 6, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: H. Steve Zhang
  • Patent number: 10362770
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: July 30, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10338060
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: July 2, 2019
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Patent number: 10301598
    Abstract: Provided herein are novel indoleacrylic acid-based compounds, and pharmaceutically acceptable salts thereof, useful for the production, maintenance and proliferation of pluripotent stem cells. Also provided are cell culture compositions comprising these compounds, and methods of using these compounds in the production and maintenance of pluripotent stem cells.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 28, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Yee Sook Cho, Kyeong Lee, Jung Woon Lee
  • Patent number: 10301599
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: May 28, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10294453
    Abstract: The present invention relates to a method for increasing the stemness of human mesenchymal stem cells and, more particularly, to: a method for increasing the stemness of human mesenchymal stem cells by means of endothelin-1 treatment; the human mesenchymal stem cells having increased stemness by using the method; and a composition for increasing the stemness of human mesenchymal stem cells, containing endothelin-1 as an active ingredient. In the present invention, it is confirmed that the expression of a stemness marker is increased and that a stem cell characteristic is improved such as the length of telomeres being extended, by treating human mesenchymal stem cells with endothelin-1, and thus cellular life span is extended, aging is inhibited, and the growth and viability of cells are increased, thereby enabling mass culturing of human mesenchymal stem cells such that human mesenchymal stem cells are expected to be used effectively in cell therapy or regenerative medicine.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: May 21, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Hyo-Soo Kim, Eun Ju Lee
  • Patent number: 10287606
    Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: May 14, 2019
    Assignee: Fate Therapeutics, Inc.
    Inventors: Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl